BRPI0716145A2 - formuaÇço de vacina, mÉtodo de adaptaÇço e propagaÇço do vÍrus chikungunya, mÉtodo de concentraÇço e purificaÇço de vÍrus, composiÇço potencialmente imunogÊnica, sequÊncia de nucleotÍdeo, contruto de dna recombinante, mÉtodo para produzir proteÍna recombinante, composiÇço farmacÊutica, mÉtodo in vitro ou in vivo e mÉtodo para elicitar resposta imune protetora - Google Patents
formuaÇço de vacina, mÉtodo de adaptaÇço e propagaÇço do vÍrus chikungunya, mÉtodo de concentraÇço e purificaÇço de vÍrus, composiÇço potencialmente imunogÊnica, sequÊncia de nucleotÍdeo, contruto de dna recombinante, mÉtodo para produzir proteÍna recombinante, composiÇço farmacÊutica, mÉtodo in vitro ou in vivo e mÉtodo para elicitar resposta imune protetoraInfo
- Publication number
- BRPI0716145A2 BRPI0716145A2 BRPI0716145-0A2A BRPI0716145A BRPI0716145A2 BR PI0716145 A2 BRPI0716145 A2 BR PI0716145A2 BR PI0716145 A BRPI0716145 A BR PI0716145A BR PI0716145 A2 BRPI0716145 A2 BR PI0716145A2
- Authority
- BR
- Brazil
- Prior art keywords
- vitro
- composition
- nucleotide sequence
- immune response
- dna construct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
- C12N2770/36163—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1583CH2006 | 2006-09-01 | ||
IN1583/CHE/2006 | 2006-09-01 | ||
PCT/IN2007/000383 WO2008026225A2 (en) | 2006-09-01 | 2007-08-31 | A vaccine for chikungunya virus infection |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0716145A2 true BRPI0716145A2 (pt) | 2013-09-17 |
BRPI0716145B1 BRPI0716145B1 (pt) | 2021-06-22 |
Family
ID=39136377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0716145-0A BRPI0716145B1 (pt) | 2006-09-01 | 2007-08-31 | Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya |
Country Status (5)
Country | Link |
---|---|
US (1) | US8865184B2 (pt) |
EP (1) | EP2073839B1 (pt) |
CN (1) | CN101516395B (pt) |
BR (1) | BRPI0716145B1 (pt) |
WO (1) | WO2008026225A2 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2545597A1 (en) * | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
CA2598966A1 (en) * | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
ES2588738T3 (es) | 2008-04-04 | 2016-11-04 | The Trustees Of The University Of Pennsylvania | Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas |
EP2281070B1 (en) | 2008-04-21 | 2015-01-21 | Gen-Probe Incorporated | Method for detecting chikungunya virus |
SG171828A1 (en) | 2008-11-26 | 2011-07-28 | Us Gov Health & Human Serv | Virus like particle compositions and methods of use |
US9101572B2 (en) * | 2009-12-31 | 2015-08-11 | Medigen, Inc. | Infectious DNA vaccines against chikungunya virus |
WO2011124635A1 (en) | 2010-04-07 | 2011-10-13 | Humalys | Binding molecules against chikungunya virus and uses thereof |
EP2374816B1 (en) * | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
SG184833A1 (en) * | 2010-04-14 | 2012-11-29 | Emd Millipore Corp | Methods of producing high titer, high purity virus stocks and methods of use thereof |
CN103228293A (zh) * | 2010-11-30 | 2013-07-31 | 巴拉特生物技术国际有限公司 | 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂 |
CN103476788A (zh) * | 2010-12-10 | 2013-12-25 | 新加坡科技研究局 | 免疫原性屈曲病毒肽 |
JP6147734B2 (ja) * | 2011-06-17 | 2017-06-14 | バハラ バイオテック インターナショナル リミテッド | 不活化チクングニアウイルス株を含むワクチン組成物 |
CN111729077A (zh) | 2013-03-14 | 2020-10-02 | 武田疫苗股份有限公司 | 减毒活甲病毒制剂的组合物和方法 |
CN108601825B (zh) * | 2015-07-16 | 2023-06-20 | 巴拉特生物技术国际有限公司 | 疫苗组合物 |
WO2017109228A1 (en) * | 2015-12-23 | 2017-06-29 | Valneva Austria Gmbh | Zika virus purification |
WO2017123932A1 (en) * | 2016-01-13 | 2017-07-20 | United States, As Represented By The Secretary Of The Army | Inactived vaccine for chikungunya virus |
KR20180135912A (ko) | 2016-03-31 | 2018-12-21 | 다케다 백신즈 인코포레이티드 | 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법 |
CN105906694B (zh) * | 2016-05-05 | 2019-05-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 基孔肯亚病毒特异性检测抗原及其应用 |
WO2017197034A1 (en) * | 2016-05-10 | 2017-11-16 | Najit Technologies, Inc. | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production |
US11033615B2 (en) | 2016-05-31 | 2021-06-15 | The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland | Zika virus vaccine and methods of production |
AU2018298499A1 (en) * | 2017-07-03 | 2020-02-20 | Bharat Biotech International Limited | A synthetic polypeptide epitope based vaccine composition |
CN111263642A (zh) | 2017-09-21 | 2020-06-09 | 瓦尔尼瓦公司 | 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法 |
CN111615397A (zh) | 2017-11-03 | 2020-09-01 | 武田疫苗股份有限公司 | 寨卡疫苗和免疫原性组合物及其使用方法 |
CN111601885A (zh) | 2017-11-30 | 2020-08-28 | 武田疫苗股份有限公司 | 用于将寨卡病毒灭活的方法和相关方法 |
US10718771B2 (en) | 2018-02-09 | 2020-07-21 | Chung Yuan Christian University | Recombinant baculoviruses and their uses in detecting arthropod-borne virus |
EP3530668A1 (en) | 2018-02-22 | 2019-08-28 | Euroimmun Medizinische Labordiagnostika AG | A novel assay for the diagnosis of viral infections |
EP3755709A1 (en) | 2018-02-22 | 2020-12-30 | Euroimmun Medizinische Labordiagnostika AG | Assay for the diagnosis of viral infections |
BR102020012760A2 (pt) | 2019-07-02 | 2022-03-08 | Euroimmun Medizinische Labordiagnostika Ag | Ensaio para o diagnóstico de infecções causadas por nematodos |
CN114828881A (zh) * | 2019-10-25 | 2022-07-29 | 伊美根特旅行健康公司 | 基孔肯雅病毒样颗粒疫苗及其使用方法 |
CN117771353B (zh) * | 2024-02-27 | 2024-05-14 | 中国医学科学院医学生物学研究所 | 一种以包膜蛋白为靶标的基孔肯雅病毒的mRNA疫苗及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008030220A2 (en) * | 2005-08-11 | 2008-03-13 | The Board Of Regents Of The University Of Texas System | Chikungunya virus infectious clones and uses thereof |
CA2545597A1 (en) * | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
-
2007
- 2007-08-31 WO PCT/IN2007/000383 patent/WO2008026225A2/en active Application Filing
- 2007-08-31 EP EP07827554.2A patent/EP2073839B1/en active Active
- 2007-08-31 US US12/439,509 patent/US8865184B2/en active Active
- 2007-08-31 BR BRPI0716145-0A patent/BRPI0716145B1/pt active IP Right Grant
- 2007-08-31 CN CN200780035576.XA patent/CN101516395B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
EP2073839B1 (en) | 2016-10-19 |
EP2073839A2 (en) | 2009-07-01 |
CN101516395B (zh) | 2014-03-26 |
US8865184B2 (en) | 2014-10-21 |
BRPI0716145B1 (pt) | 2021-06-22 |
CN101516395A (zh) | 2009-08-26 |
US20130022631A1 (en) | 2013-01-24 |
WO2008026225A3 (en) | 2008-09-25 |
WO2008026225A2 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0716145A2 (pt) | formuaÇço de vacina, mÉtodo de adaptaÇço e propagaÇço do vÍrus chikungunya, mÉtodo de concentraÇço e purificaÇço de vÍrus, composiÇço potencialmente imunogÊnica, sequÊncia de nucleotÍdeo, contruto de dna recombinante, mÉtodo para produzir proteÍna recombinante, composiÇço farmacÊutica, mÉtodo in vitro ou in vivo e mÉtodo para elicitar resposta imune protetora | |
MX2014004214A (es) | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. | |
WO2010066418A8 (de) | Verwendung von flt3-ligand zur verstärkung von immunreaktionen bei rna-immunisierung | |
EP2023952A4 (en) | INDUCTION OF IMMUNE REACTIONS TO THE INFLUENZA AVIRUSES USING POLYPEPITD AND NUCLEIC ACID COMPOSITIONS | |
EP2069376A4 (en) | INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS | |
BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
WO2012069655A3 (en) | Improved capping modules for designed ankyrin repeat proteins | |
DK2154990T3 (da) | Funktionelt serumproteinprodukt til anvendelse i spædbørnsernæring samt terapeutiske sammensætninger og fremgangsmåder til deres fremstilling | |
AR077757A1 (es) | Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
BRPI0906997A2 (pt) | Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica | |
BRPI0811193A2 (pt) | Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo. | |
IL187321A (en) | Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation | |
EP1989316A4 (en) | METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS | |
IN2012DN03209A (pt) | ||
BRPI0921424A2 (pt) | vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. | |
JP2011517938A5 (pt) | ||
BRPI1012078A2 (pt) | construto de proteína, composição imunogênica, molécula de ácido nucleico , métodos de induzir uma resposta imune a casb7439 e de tratar um animal humano ou não-humano, e, uso de uma composição imunogênica | |
WO2011053065A3 (ko) | 카테콜 폴리에틸렌글리콜 유도체와 단백질 또는 펩타이드의 접합체 및 이의 제조방법 | |
WO2009074861A3 (en) | Improved vaccine | |
BRPI0906044A2 (pt) | "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas" | |
WO2014046622A1 (en) | Novel attenuated dengue virus strains for vaccine application | |
Sanicas et al. | A review of COVID-19 vaccines in development: 6 months into the pandemic | |
AP1724A (en) | Attenuated strains of vibrio cholerae with improved biological safety features in freeze dried form for oral vaccination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B65X | Notification of requirement for priority examination of patent application | ||
B65Z | Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117) | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |